Amylyx (AMLX) | Financial Analysis & Statements
Amylyx Pharmaceuticals Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Gross Profit
0
Operating Income
-36.6M
Net Income
-33.0M
EPS (Diluted)
$-0.30
Balance Sheet Metrics
Total Assets
332.6M
Total Liabilities
27.4M
Shareholders Equity
305.3M
Debt to Equity
0.09
Cash Flow Metrics
Operating Cash Flow
-26.3M
Free Cash Flow
-28.0M
Revenue & Profitability Trend
Amylyx Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 87.4M | 380.8M | 22.2M | 0 |
| Cost of Goods Sold | 0 | 124.6M | 25.4M | 3.0M | 0 |
| Gross Profit | 0 | -37.3M | 355.3M | 19.2M | 0 |
| Gross Margin % | 0.0% | -42.6% | 93.3% | 86.5% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 90.4M | 104.1M | 128.2M | 93.4M | 44.0M |
| Selling, General & Administrative | 62.9M | 114.3M | 188.4M | 127.1M | 38.9M |
| Other Operating Expenses | - | - | - | - | -285.0K |
| Total Operating Expenses | 153.3M | 218.4M | 316.5M | 220.6M | 82.7M |
| Operating Income | -153.3M | -255.7M | 38.8M | -201.3M | -82.7M |
| Operating Margin % | 0.0% | -292.6% | 10.2% | -905.7% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 9.3M | 13.8M | 16.2M | 4.3M | 36.0K |
| Interest Expense | - | - | - | - | 0 |
| Other Non-Operating Income | -700.0K | -60.3M | -660.0K | -551.0K | -5.3M |
| Pre-tax Income | -144.7M | -302.1M | 54.3M | -197.6M | -87.9M |
| Income Tax | 46.0K | -393.0K | 5.0M | 774.0K | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 9.3% | 0.0% | 0.0% |
| Net Income | -144.7M | -301.7M | 49.3M | -198.4M | -87.9M |
| Net Margin % | 0.0% | -345.4% | 12.9% | -892.4% | 0.0% |
| Key Metrics | |||||
| EBITDA | -152.8M | -195.7M | 39.9M | -200.9M | -82.6M |
| EPS (Basic) | - | $-4.43 | $0.73 | $-3.39 | $-1.59 |
| EPS (Diluted) | - | $-4.43 | $0.70 | $-3.39 | $-1.59 |
| Basic Shares Outstanding | - | 68142158 | 67234465 | 58495587 | 55216013 |
| Diluted Shares Outstanding | - | 68142158 | 67234465 | 58495587 | 55216013 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Amylyx Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 226.7M | 77.4M | 170.2M | 62.5M | 50.2M |
| Short-term Investments | 90.3M | 99.1M | 201.2M | 284.4M | 45.9M |
| Accounts Receivable | 88.0K | 447.0K | 40.0M | 15.3M | 0 |
| Inventory | - | 0 | 38.3M | 9.8M | 0 |
| Other Current Assets | 6.6M | 12.5M | 14.9M | 10.1M | 5.4M |
| Total Current Assets | 323.7M | 189.4M | 464.7M | 382.1M | 105.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 5.2M | 1.8M | 3.7M | 5.5M | 0 |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 3.5M | 1.5M | 46.4M | 1.2M | 189.0K |
| Total Non-Current Assets | 9.0M | 4.2M | 52.8M | 9.3M | 663.0K |
| Total Assets | 332.6M | 193.6M | 517.5M | 391.5M | 105.6M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 3.5M | 2.9M | 22.1M | 6.3M | 4.4M |
| Short-term Debt | 1.3M | 1.5M | 2.3M | 2.0M | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | 4.6M | - |
| Total Current Liabilities | 22.7M | 28.4M | 82.0M | 46.6M | 17.4M |
| Non-Current Liabilities | |||||
| Long-term Debt | 4.7M | 463.0K | 2.0M | 4.2M | 0 |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 4.7M | 463.0K | 2.0M | 4.2M | 239.4M |
| Total Liabilities | 27.4M | 28.9M | 84.0M | 50.8M | 256.8M |
| Equity | |||||
| Common Stock | 11.0K | 7.0K | 7.0K | 7.0K | 1.0K |
| Retained Earnings | -751.4M | -606.7M | -304.9M | -354.2M | -155.8M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 305.3M | 164.8M | 433.4M | 340.6M | -151.2M |
| Key Metrics | |||||
| Total Debt | 6.0M | 2.0M | 4.2M | 6.3M | 0 |
| Working Capital | 301.0M | 161.0M | 382.6M | 335.5M | 87.6M |
Balance Sheet Composition
Amylyx Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -144.7M | -301.7M | 49.3M | -198.4M | -87.9M |
| Depreciation & Amortization | 525.0K | 904.0K | 1.1M | 487.0K | 52.0K |
| Stock-Based Compensation | 27.6M | 33.0M | 37.2M | 21.7M | 3.1M |
| Working Capital Changes | 1.5M | 9.0M | -82.4M | -22.5M | 651.0K |
| Operating Cash Flow | -115.2M | -221.6M | 5.1M | -198.6M | -78.9M |
| Investing Activities | |||||
| Capital Expenditures | -138.0K | -157.0K | -1.2M | -2.5M | -353.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -231.8M | -232.0M | -300.8M | -415.9M | -49.1M |
| Investment Sales | 246.0M | 344.0M | 394.1M | 179.4M | 3.0M |
| Investing Cash Flow | 14.0M | 75.7M | 92.1M | -239.0M | -46.4M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | 0 | 0 | 26.2M |
| Debt Repayment | - | - | 0 | 0 | -263.0K |
| Financing Cash Flow | 253.0M | -1.8M | -3.5M | 429.6M | 158.2M |
| Free Cash Flow | -123.5M | -167.8M | 10.7M | -182.4M | -75.2M |
| Net Change in Cash | 151.8M | -147.8M | 93.7M | -8.0M | 32.9M |
Cash Flow Trend
Amylyx Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
2.54
Forward P/E
-14.30
Price to Book
6.31
PEG Ratio
-0.06
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-61.59%
Return on Assets
-36.41%
Financial Health
Current Ratio
14.27
Debt to Equity
1.95
Beta
-0.21
Per Share Data
EPS (TTM)
$-1.53
Book Value per Share
$2.78
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AMLX | 1.9B | 2.54 | 6.31 | -61.59% | 0.00% | 1.95 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






